



12 July 2021

***By Electronic Lodgement***

Market Announcements Office  
Australian Securities Exchange Limited  
Sydney NSW 2000

Dear Sir/Madam,

**Antipodes Global Shares (Quoted Managed Fund) (ASX:AGX1) – Monthly Investment Update**

Please find attached a copy of the investment update for the month ending 30 June 2021.

For further information, please contact 1300 010 311.

Authorised by:

Calvin Kwok  
Company Secretary

**Pinnacle Fund Services Limited as responsible entity of Antipodes Global Shares (Quoted Managed Fund)**

## Commentary

Global equity strength continued in June (+4.1%) led by the Technology and Energy sectors, while Materials and Financials underperformed. US equities (+5.5%) outperformed amidst the continuation of friendly policy from the US Federal Reserve despite the emergence of more hawkish tones. European equities underperformed (+1.1%) as the continent continued to catchup with its vaccination rollout.

Asian equities were stable (+3.0%) with Japan (+1.7%) underperforming, while Chinese equities were positive despite their continued regulation on internet names and commodity prices (+3.4%).

Elsewhere, Brent Crude (+10.8% in USD) continued its rally, while Gold underperformed (-7.2% in USD) and the US Dollar (DXY +2.9%) was stronger driven by the US macroeconomic backdrop.

Key contributors included:

- Software/Internet - Developed Markets cluster, notably Microsoft amidst continued strength in the company's cloud services business, Facebook as a US federal court dismissed the Federal Trade Commission's antitrust lawsuit, and Roku as they announced a record two-week streaming period from the launch of original content.
- Software/Internet - Asia/Emerging Markets cluster, notably Meituan after reporting strong growth in food delivery, supporting its dominant market status. JD.com experienced an increase in sales from the prior year from

the 618 shopping festival in China with over 80% of new users coming from lower tier cities.

- Healthcare cluster, notably Merck following the presentation of impressive data at a medical conference (ASCO), supporting its oncology therapy pipeline, and as major pharmaceutical stocks rebounded after a period of underperformance.
- Exxon, in our Energy cluster, continued its upward trajectory in tandem with rallying crude oil prices and increased investor confidence in de-risking the long term strategy following the successful election of new board directors with specialisations in decarbonisation.

Key detractors included:

- Consumer Cyclical - Asia/EM cluster including Trip.com after a brief resurgence of COVID-19 cases in the Guangdong region in China raised concerns of delays to the establishment of travel bubbles. Financials, including KB Financial, underperformed as the consensus on rising rates was challenged after bonds rallied on concerns that the recovery trade may not be as linear as expected.
- Volkswagen in the Industrials cluster after a sustained period of outperformance over the prior two quarters.
- Newcrest Mining on the weakness in gold.

## Net performance (%)

	Fund	Benchmark	Difference
1 month	1.0	4.5	-3.4
3 month	3.2	9.0	-5.7
Year to date	11.9	15.4	-3.5
1 year	28.7	27.7	0.9
Inception p.a.	11.1	15.9	-4.7
Inception	32.3	47.8	-15.5

Past performance is not a reliable indicator of future performance. Returns are calculated net of applicable fees, costs and taxes.

## Top 10 equity longs (%)

Name	Country	Weight
Facebook	United States	4.5
Siemens	Germany	3.5
Microsoft	United States	3.4
Samsung Electronics	Korea	2.6
Tencent	China/HK	2.5
ING Groep	Netherlands	2.4
Taiwan Semiconductor	Taiwan	2.3
Exxon Mobil	United States	2.3
Merck	United States	2.2
General Electric	United States	2.2

## iNAV tickers


	Unit Price	iNAV
Bloomberg	AGX1.AU Equity	AGFLIV Index
Thomson Reuters	AGX1.AX	AGFLOFV=SOLA
IRESS	AGX1.AXW, AGX1.CXA	AGXIIV

## Fund facts

Characteristics	
Investment manager	Antipodes Partners
Inception date	5 November 2018
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.10% p.a.
Performance fee	15% of net return in excess of benchmark
Distribution	Annual, 30 June
Unit valuation	Sydney business day

Asset value	
Fund AUM	\$26m
Strategy AUM	\$3,061m
Asset Value (NAV)	5.7031

## Sector exposure<sup>1</sup> (%)




<sup>1</sup> Antipodes classification

Asset allocation<sup>3</sup>

	Equities - Long	Other - Long
Weight (%)	92.3	-
Count	59	-
Avg. weight (%)	1.6	-
Top 10 (%)	28.0	-
Top 30 (%)	65.9	-

<sup>3</sup> Call (put) options represented as the current option value (delta adjusted exposure)

Currency exposure<sup>2,3</sup> (%)

<sup>2</sup> Where possible, regions, countries and currencies classified on a look through basis.

Regional exposure<sup>1,2,3</sup> (%)

Region	Long
North America	38.8
Western Europe	24.3
- Eurozone	18.6
- United Kingdom	2.9
- Rest Western Europe	2.8
Developed Asia	15.5
- Korea/Taiwan	10.5
- Japan	5.0
Developing Asia	12.3
- China/Hong Kong	10.2
- India	2.1
Australia	1.4
<b>Total Equities</b>	<b>92.3</b>
Cash	7.7
<b>Totals</b>	<b>100.0</b>

Market cap exposure<sup>3</sup> (%)

Band	Long
Mega (>\$100b)	51.0
Large (>\$25b <\$100b)	19.5
Medium (>\$5b <\$25b)	19.9
Small (<\$5b)	1.9

## Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

## Fund features

- **Objective** – to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- **Global diversification** – Access to 30+ global companies via a single trade
- **Alignment of interests** – proportion of each team member's remuneration is invested into Antipodes funds. Antipodes also has a significant investment alongside unitholders
- **Simple access** – being exchange traded, investors can buy or sell AGX1 like a regular share during the trading day

## Fund Ratings



## Further information

☎ 1300 010 311

✉ [invest@antipodespartners.com](mailto:invest@antipodespartners.com)

## Australia Head Office

Antipodes Partners Limited  
Level 35, 60 Margaret St  
Sydney NSW 2000  
Australia

## UK Office

Antipodes Partners Limited  
6th Floor, Nova North  
11 Bressenden Place  
London SW1E 5BY UK

## Disclaimer

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned October 2020) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>

The Lonsec Ratings (assigned February 2020) presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <http://www.beyond.lonsec.com.au/research-solutions/our-ratings>.

Interests in the Antipodes Global Shares (Quoted Managed Fund) ARSN 625 560 269 ('Fund') are issued by Pinnacle Fund Services Limited, ABN 29 082 494 362, AFSL 238371. Antipodes Partners Limited ABN 29 602 042 035 AFSL 481580 ('Antipodes') is the investment manager of the Fund. The Product Disclosure Statement (PDS) for the Fund is available at [www.antipodespartners.com](http://www.antipodespartners.com).

Pinnacle Fund Services Limited is not licensed to provide financial product advice. Any potential investor should consider the current PDS in its entirety and consult their financial adviser before making an investment decision in relation to the Fund. Antipodes and Pinnacle Fund Services Limited believe the information contained in this communication is reliable, however no warranty is given as to its accuracy and persons relying on this information do so at their own risk. Any opinions or forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information at the date of publication and may later change without notice. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. This communication is for general information only. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is not a reliable indicator of future performance.

To the extent permitted by law, Antipodes and Pinnacle Fund Services Limited disclaim all liability to any person relying on the information in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information contained in this communication. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value.